Junshi Reports NMPA’s Acceptance of sNDA for Toripalimab + CT as 1L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Junshi Reports NMPAs Approval of sNDA for Toripalimab + CT as 1L Treatment for Advanced or Metastatic Esophageal Squamous Cell Cancer

Shots:

The sNDA is based on the P-III JUPITER-06 research study examining toripalimab + CT vs PBO + CT in 514 clients with locally advanced or metastatic ESCC
The outcomes of the research study showed that toripalimab + CT significantly enhanced both PFS and OS for patients with advanced or metastatic ESCC, no matter PD-L1 expression status. The data will exist quickly at ESMO 2021
Toripalimab is the very first domestic anti-PD-1 mAb acquiring marketing approval in China and has furthermore received BTD, FTD & & ODD from FDA for the treatment of mucosal melanoma, nasopharyngeal cancer, and soft tissue sarcoma

Click here to read full press release/ article|Ref: Globe Newswire|Image: PR Newswire

Post Views:
2